Genentech Presents Interim Phase III Sefaxersen Data in IgA Nephropathy

Genentech said interim data from its ongoing Phase III IMAgINATION study showed investigational sefaxersen significantly reduced proteinuria in adults with primary IgA nephropathy receiving optimized standard of care.